– UK, York – OptiBiotix Health plc (LON: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, diabetes, and skincare, today announced that it intends to appoint Stephen Hammond MP to its Board as a Non- Executive Director, subject to the completion of regulatory due diligence.
“Stephen’s appointment reflects the continued evolution and ambition of the Board as the Company moves into the next phase of its development in becoming a profitable international business with global brands. Stephen’s international understanding of healthcare, finance and experience of working in senior positions within finance and government complements the current Board’s wealth of experience.” said Board Chairman, Neil Davidson.
He added: “The Company anticipates that there will be further additions and changes to the Board and management teams as it continues to grow sales, expand into international markets, and commercializes its next-generation products.”
About Stephen Hammond
Stephen has been a Member of Parliament since 2005, fulfilling roles as Parliamentary Under-Secretary of State for Transport from 2012 to 2014 and more recently Minister of State for the Department of Health and Social Care from 2018 to 2019.
Before his role in politics, Stephen had a successful career in finance at a leading fund management house and several major European investment banks. He was a Director of the Equities division of Dresdner Kleinwort Benson from 1994 to 1998, a private bank providing financial services to high net worth individuals and corporate clients in the UK. After this, he joined Commerzbank Securities, a leading international commercial bank described as ‘Germany’s Leading Brokerage Firm’ of the past 10 years, with branches and offices in nearly 50 countries. He was with Commerzbank Securities from 1998 until 2003. During this time, Stephen was promoted to Director in Pan European Research, with the responsibility for 70 professionals based in London and across Europe, before becoming an MP in 2005.
About OptiBiotix
OptiBiotix Health plc which was formed in March 2012, brings science to the development of compounds which modify the human microbiome – the collective genome of the microbes in the body – to prevent and manage human disease and promote wellness.
OptiBiotix has an extensive R&D program working with leading academics in the development of microbial strains, compounds, and formulations which are used as active ingredients and supplements. More than twenty international food and healthcare supplement companies have signed agreements with OptiBiotix to incorporate their human microbiome modulators into a wide range of food products and drinks.
OptiBiotix is also developing its own range of consumer supplements and health products. The Company’s current areas of focus include obesity, cardiovascular health, and diabetes.
For more information: https://optibiotix.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
